+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

2019 Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025

  • ID: 4768248
  • Report
  • 51 pages
  • VPA Research
1 of 3

FEATURED COMPANIES

  • Abeona Therapeutics Inc
  • Astellas Pharma Inc
  • Fate Therapeutics Inc
  • Lysogene SAS
  • Nuo Therapeutics Inc
  • Royal DSM NV
  • MORE
The global clinical trial report- “2019 Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Clinical Trials Study” provides complete list of trials completed, ongoing and planned for Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ). It presents in-depth analysis of Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) clinical trials across markets and companies. The research work is for providing complete understanding into trends in Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ).

The report covers a key snapshot of trial trends, enrollment trends, success trends, locations and other trends.

It also segments the Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) clinical trials by:
  • Current Trial Status
  • Type of the trial
  • Sponsor Type
  • Enrollment Trends
  • Region
  • Countries
  • Trial Phase
The report also identifies the potential drug candidates under development for treatment of Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome )

The research work is prepared through extensive and continuous research on Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) trials from over 1500 sources including company websites, conferences and presentations, scientific journals, country wise and global clinical trial registries, news, health and science departments among others.

Report Scope and Coverage:
  • All major trials from 2010 to 2019 and planned trials are included in the report scope.
  • Drug candidates currently being researched for administering Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) patients are identified
  • The report includes panorama of Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) clinical trials across the globe
  • Trial Phase, Current Status, Sponsor Type, Location, trial type and Enrollment details are provided
  • Companies and universities focusing on Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) clinical trials are analyzed along with their trial participation (trial title, trial phase and current status)
  • Average Enrollment number, insights into enrollment trends, company wise enrollment are included
  • Both interventional and observational studies are analyzed
  • News and latest developments for the past one year are presented in the report
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Abeona Therapeutics Inc
  • Astellas Pharma Inc
  • Fate Therapeutics Inc
  • Lysogene SAS
  • Nuo Therapeutics Inc
  • Royal DSM NV
  • MORE
1.1 List of Figures
1.2 List of Tables

2. Executive Summary
2.1 Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Clinical Trials Overview, 2019
2.2 Premium Insights into Clinical Trials
2.2.1 Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Clinical Trials by Region
2.2.2 Average Enrollment of Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Clinical Trials
2.2.3 Companies participating in Trials
2.2.4 Drugs under Study for Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Treatment, 2019

3. Region wise Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Clinical Trials
3.1 Asia Pacific Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Clinical Trials by Country
3.2 Europe Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Clinical Trials by Country
3.3 North America Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Clinical Trials by Country
3.4 Middle East and Africa Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Clinical Trials by Country
3.5 South and Central America Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Clinical Trials by Country

4. Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Clinical Trial Trends
4.1 Start Year wise Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Clinical Trials
4.2 Phase wise Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Clinical Trials
4.3 Trial Status wise Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Clinical Trials
4.4 Trial Type wise Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Clinical Trials

5. Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Average Enrollment Trends
5.1 Average Enrollment in Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Trials by Year
5.2 Average Enrollment in Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Trials by Phase
5.3 Average Enrollment in Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Trials by Status
5.4 Average Enrollment in Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Trials by Type of Trial

6. Companies Participating in Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Clinical Trials
6.1 Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Trials by Sponsor Type
6.2 Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Average Enrollment by Sponsor Type
6.3 Subjects Recruited by Leading Sponsors

7. Trial Snapshots- Phase, Type, Title, Location, Start Year, Completion Year, Recruitment Status, Enrollment, Participating Countries, Trial Locations, Company, Drugs and Other Details
7.1 Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Trials- Phase 1
7.2 Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Trials- Phase 2
7.3 Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Trials- Phase 3
7.4 Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Trials- Phase 4

8. Appendix
8.1 Report Guidance
8.2 Research Methodology
8.3 Abbreviations
8.4 Definitions
8.5 Sources
8.6 Publisher Expertise

List of Figures
Figure 1: Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Clinical Trials by Region, 2019
Figure 2: Country wise Clinical Trials, 2019
Figure 3: Country wise Average Enrolment, 2019
Figure 4: Asia Pacific - Country wise Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Clinical Trials and Enrolment
Figure 5: Europe - Country wise Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Clinical Trials and Enrolment
Figure 6: Middle East Africa - Country wise Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Clinical Trials and Enrolment
Figure 7: North America - Country wise Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Clinical Trials and Enrolment
Figure 8: South and Central America - Country wise Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Clinical Trials and Enrolment
Figure 9: Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Clinical Trials by Phase
Figure 10: Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Clinical Trials by Trial Status
Figure 11: Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Clinical Trials by Type
Figure 12: Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Clinical Trials by Sponsor Type
Figure 13: Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Clinical Trials by Leading Sponsors
Figure 14: Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Average Enrollment by Phase
Figure 15: Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Average Enrollment by Trial Status
Figure 16: Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Average Enrollment by Type
Figure 17: Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome )- Average Enrolment by Type of Sponsors
Figure 18: Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome )- Enrolment by Leading Sponsors
Figure 19: Research Methodology

List of Tables
Table 1: Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Clinical Trials Snapshot- 2019
Table 2: Trials by Region, 2019
Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019
Table 4: Asia Pacific - Country wise Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Clinical Trials and Enrolment
Table 5: Europe - Country wise Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Clinical Trials and Enrolment
Table 6: Middle East Africa - Country wise Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Clinical Trials and Enrolment
Table 7: North America - Country wise Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Clinical Trials and Enrolment
Table 8: South and Central America - Country wise Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Clinical Trials and Enrolment
Table 9: Clinical Trials by Phase
Table 10: Clinical Trials by Trial Status
Table 11: Clinical Trials by Type
Table 12: Clinical Trials by Sponsor Type
Table 13: Clinical Trials by Leading Sponsors
Table 14: Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Average Enrollment by Phase
Table 15: Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Average Enrollment by Trial Status
Table 16: Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Average Enrollment by Type
Table 17: Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome )- Average Enrolment by Type of Sponsors
Table 18: Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome )- Enrolment by Leading Sponsors
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Abeona Therapeutics Inc
  • Alexion Pharmaceuticals Inc
  • Astellas Pharma Inc
  • BioMarin Pharmaceutical Inc
  • Fate Therapeutics Inc
  • Laboratorios Del Dr Esteve SA
  • Lysogene SAS
  • Nuo Therapeutics Inc
  • Royal DSM NV
  • Shire Plc
Note: Product cover images may vary from those shown
Adroll
adroll